Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Widespread gene transfer to the retina is challenging as it requires vector systems to overcome physical and biochemical barriers to enter and diffuse throughout retinal tissue. We investigated whether exosome-associated adeno-associated virus, (exo-AAV) enabled broad retinal targeting following intravitreal (IVT) injection, as exosomes have been shown to traverse biological barriers and mediate widespread distribution upon systemic injection. We packaged an AAV genome encoding green fluorescent protein (GFP) into conventional AAV2 and exo-AAV2 vectors. Vectors were IVT injected into the eyes of adult mice. GFP expression was noninvasively monitored by fundus imaging and retinal expression was analyzed 4 weeks post-injection by qRT-PCR and histology. Exo-AAV2 outperformed conventional AAV2 in GFP expression based on fundus image analysis and qRT-PCR. Exo-AAV2 demonstrated deeper penetration in the retina, efficiently reaching the inner nuclear and outer plexiform, and to a lesser extent the outer nuclear layer. Cell targets were ganglion cells, bipolar cells, Müller cells, and photoreceptors. Exo-AAV2 serves as a robust gene delivery tool for murine retina, and the simplicity of production and isolation should make it widely applicable to basic research of the eye.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Exo-AAV had improved ability to cross the inner limiting membrane of the retina after intravitreal injection in mice (146).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [146]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Routes and mechanisms of extracellular vesicle uptake
Mulcahy, L. A., Pink, R. C., & Carter, D. R. F. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.24641 · Cited by 2,832
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles
György, B., Szabó, T. G., Pásztói, M., Pál, Z., Misják, P., Aradi, B., László, V., Pállinger, É., Pap, E., Kittel, Á., et al. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0689-3 · Cited by 2,074
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Yang, T., Martin, P., Fogarty, B., Brown, A., Schurman, K., Phipps, R., Yin, V. P., Lockman, P., & Bai, S. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1593-y · Cited by 975 · cited 1×
“Since exosomes can cross the blood brain barrier 17,18 , and we have shown exo-AAV to cross an endothelial barrier 16 , we hypothesized that exosomes might also facilitate penetration of AAV vectors across other barriers, such as between the vitreous and the retina.”
Christianson, H. C., Svensson, K. J., van Kuppevelt, T. H., Li, J.-P., & Belting, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304266110 · Cited by 903 · cited 1×
“Our group and others have shown extracellular vesicles to be heparin sensitive in their ability to enter cells 22–24 .”
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
A pathogenic picornavirus acquires an envelope by hijacking cellular membranes
Feng, Z., Hensley, L., McKnight, K. L., Hu, F., Madden, V., Ping, L., Jeong, S.-H., Walker, C., Lanford, R. E., & Lemon, S. M. (2013) · Nature · doi:10.1038/nature12029 · Cited by 713
Cited by
Items 101–167 of 167
The brain-joint axis: links between osteoarthritis and neurodegenerative disorders in aging
Rabie, M. A., Madry, H., Cucchiarini, M., & Sayed, N. S. E. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.023 · Cited by 16
Extracellular vesicles as a potential therapeutic for age-related macular degeneration
Chow, L. L. C., & Mead, B. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.367835 · Cited by 12
“There is continued research on the use of exosomes as a drug delivery vehicle into the eye, utilizing exosome ability to deliver compounds while loading them with known therapeutic agents (Wassmer et al., 2017; Zhang et al., 2019a; Dong et al., 2021).”
BackgroundShao, W., Huang, W., Wang, Y., Sima, H., Ma, K., Chen, R., Han, H., Yang, Y., Bao, Y., Pei, X., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13040823 · Cited by 13
“Furthermore, exosome-associated AAV vectors have been shown to mediate significantly higher transduction efficiency in target organs when delivered to mice compared to conventional AAV vectors [39,40].”
Clerck, K. D., Smedt, S. C. D., Remaut, K., & Peynshaert, K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113849 · Cited by 11
Extracellular Vesicles as Biomarkers and Therapeutics for Inflammatory Eye Diseases
Louie, H. H., Mugisho, O. O., Chamley, L. W., & Rupenthal, I. D. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00414 · Cited by 11
Induction of a proliferative response in the zebrafish retina by injection of extracellular vesicles
Didiano, D., Abner, J. J., Hinger, S. A., Flickinger, Z., Kent, M. R., Clement, M. A., Balaiya, S., Liu, Q., Dai, X., Levine, E. M., et al. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108254 · Cited by 11
“AAV2 vectors that are associated with exosomes are also capable of gene delivery in the murine retina (Wassmer et al., 2017).”
BackgroundPathophysiology of spinal cord injury and advanced therapeutic approaches
Yadav, S., & Mukherjee, S. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10785-9 · Cited by 10
Round window membrane extracellular vesicles facilitate inner ear drug delivery
Holdsclaw, S., Silkstone, D., Moazzam, F., Jeanneret, H., Tehsin, N., Norris, E., Talic, E., Popowski, K. D., Cruse, G., Cheng, K., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114153 · Cited by 12
“Importantly, EVs have been shown to successfully traverse biological barriers, including the blood-brain and vitreous-retina interfaces, while maintaining the activity of their cargo via transcellular transport and passage through tight junctions [46–48].”
Recording and Analysis of Goldmann Kinetic Visual Fields
Talib, M., Dagnelie, G., & Boon, C. J. F. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_24 · Cited by 11
“Although ongoing subretinal gene therapy trials have targeted the central retina [3, 8, 9], possible intravitreal gene therapy administration in the future could target the whole retina [10, 11], further necessitating the Goldmann visual field (GVF) to evaluate the potential therapeutic effect.”
BackgroundZhang, S., Qiu, Y., Feng, Y., Zhang, Y., Li, Y., Wang, B., Wei, H., Chen, X., Shen, L., Li, W., et al. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/3310621 · Cited by 10
“Exosomes perform important roles in both physiological and pathological processes in AMD [34, 35].”
BackgroundExtracellular vesicles as reconfigurable therapeutics for eye diseases: Promises and hurdles
Shekari, F., Abyadeh, M., Meyfour, A., Mirzaei, M., Chitranshi, N., Gupta, V., Graham, S. L., & Salekdeh, G. H. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102437 · Cited by 11
Unveiling the potential of bacterial cellulose-based composites in eye tissue engineering: a review
Jabbari, F., Mohammadi, S., & Babaeipour, V. (2024) · International Journal of Polymeric Materials · doi:10.1080/00914037.2024.2368895 · Cited by 12
Matsuzaka, Y., Hirai, Y., Hashido, K., & Okada, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031551 · Cited by 9
Gene therapy for retinal diseases: From genetics to treatment
Khaparde, A., Mathias, G. P., Poornachandra, B., Thirumalesh, M. B., Shetty, R., & Ghosh, A. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2902_23 · Cited by 10
“[73] Previous reports suggest systemic delivery of hydroxyl‑terminated polyamidoamine dendrimer–triamcinolone acetonide conjugate in rats, with selective uptake by injured microglia/ macrophage and RPE.”
BackgroundCheng, M. L., de la Cruz, D., Crain, A. V., Espinoza, P., Ng, C., Elmore, Z. C., Asokan, A., & Maguire, C. A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101407 · Cited by 10
Self-citationGene therapy for the heart: encapsulated viruses to the rescue
Deshetty, U. M., Sil, S., & Buch, S. J. (2024) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.70 · Cited by 7
Molina, E., Tejero, M., Duzenli, O. F., Kuoch, H., Caine, C., Krotova, K. Y., Paulaitis, M. E., & Aslanidi, G. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101358 · Cited by 7
Gan, C., Leng, M., Liu, Y., Zheng, Z., He, S., Qiao, W., Lin, X., Xiao, Y., Ye, J., Zhou, L., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101399 · Cited by 7
Scientometric analysis of extracellular vesicles in vision science (up to 2024)
Liao, F., Germaín, F., Ma, L., Wei, C., & Wang, T. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03703-5 · Cited by 6
On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors
de la Mota, S., Suchet, L., van Wijk, M., Stibbs, D. J., Couto, P. S., & Rafiq, Q. A. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108907 · Cited by 6
Kovács, O. T., Soltész‐Katona, E., Marton, N., Baricza, E., Hunyady, L., Turu, G., & Nagy, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084221 · Cited by 6
In vivo retinal imaging in translational regenerative research
Sher, I., Moverman, D. J., Ketter-Katz, H., Moisseiev, E., & Rotenstreich, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4355 · Cited by 6
“Jacobson SG, Boye SL, Aleman TS, et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.”
BackgroundMethodInfluentialHua, Z., Shen, Y., & Zhou, X. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030282 · Cited by 5
“As membrane-derived natural vesicles, exosomes possess membrane fusion capabilities that enhance ILM penetration and retinal accumulation [133].”
Prabhu, M. R., Upadhya, D., Madhyastha, H., Naha, A., Perumalsamy, H., Sunderraj, S., Dubey, A., Rahimi, S., Balusamy, S. R., & Hebbar, S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04058-1 · Cited by 9
“Similar delivery to retinal tissues via Exo-AAV achieved efficient intravitreal gene transfer, penetrating both the inner nuclear and outer plexi-form layers, thereby supporting retinal repair [369].”
Choi, B.-S., Park, T., Lee, H. H., Hong, H., Chi, W., & Kim, S. (2025) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2411.11080 · Cited by 5
Trans-trigeminal transport of masseter-derived neprilysin to hippocampus
Kuwajima, Y., Nagai, M., Lee, C., Galaburda, A. M., Kobayashi, T., Nakasato, A., Silva, J. D. D., Nagai, S., & Nagai, M. (2020) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2020.104861 · Cited by 5
Maddalena, A., & Kleinlogel, S. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.934394 · Cited by 4
“Exo-AAV2 is produced using AAV serotype 2, encapsulates two AAV virions, and was shown to efficiently transduce retinal cells (Maguire et al., 2012; Wassmer et al., 2017; Wang et al., 2021).”
BackgroundAccessorizing viral vectors with extracellular vesicles for enhanced performance
Maguire, C. A. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.031 · Cited by 4
Self-citationNamdari, M., & McDonnell, F. S. (2024) · Vision Research · doi:10.1016/j.visres.2024.108522 · Cited by 5
Extracellular vesicles-associated AAVs for the treatment of Machado-Joseph disease
Henriques, C., Albuquerque, P., Rufino‐Ramos, D., Lopes, M. M., Leandro, K., Miranda, C. O., Almeida, R., Lopes-Gabriel, G., de Sousa-Lourenço, J., Lopes, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.022 · Cited by 3
Self-citationExtracellular vesicles for ophthalmic and dermal ailments
Datta, D., Bandi, S. P., Janardhanam, L. S. L., Colaco, V., Dhas, N. L., Anand, K., & Kohli, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23891-8.00011-1 · Cited by 3
Toward improved AAV gene therapies for retinal disorders: challenges and advances
Siontas, O., Brown, M., & Ahn, S. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2544497 · Cited by 3
Exosome Innovations in Ophthalmology and Sjögren’s Syndrome
Wu, K. Y., Dave, A., Nirwal, G. K., Giunta, M., Nguyen, V., & Tran, S. D. (2025) · Advances in experimental medicine and biology · doi:10.1007/5584_2025_865 · Cited by 4
Weber, S. R., Zhou, M., Zhao, Y., & Sundstrom, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816053-4.00018-3 · Cited by 3
Attia, N., Khalifa, Y. H., Mashal, M., Puras, G., & Pedraz, J. L. (2022) · Advances in experimental medicine and biology · doi:10.1007/5584_2022_754 · Cited by 4
Extracellular Vesicles: “Stealth Transport Aircrafts” for Drugs
Liu, C., Lin, X., & Su, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94502 · Cited by 3
Muhuri, M., & Gao, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29189.mmu · Cited by 2
Pajaziti, B., Michgehl, U., Blazevic, D., Fimm-Todt, F., Dütting, A., Korbmacher, B., Grote-Wessels, S., Michelfelder, S., & Mecklenburg, L. (2025) · Human Gene Therapy · doi:10.1177/10430342251376043 · Cited by 4
Virus Vectors for Optogenetic Prosthetization of the Retina
Rotov, A. Y., Nikolaeva, D. A., Astakhova, L. A., & Firsov, M. L. (2020) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-020-00911-4 · Cited by 2
Optogenetic stimulation of the cochlea
de la Morena, D. L. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7546 · Cited by 2
Vorobieva, I., Luchner, M., Friedrichsen, H., Makkar, R., Chester, S., Haughton, E., Conceiao, M., Steel, H., Sanders, S. J., Wood, M. P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.12.693981 · Cited by 2
Gene Therapy of Extracellular Vesicles in Cardiovascular and Metabolic Diseases
Kovács, Á. F. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-1443-2_14 · Cited by 1
Essayagh, S., Aridi, T. G., Turunen, T., Choi, L. Y., Adam, H., Patel, N., Scali, S. T., Fisher, M. D., Skaf, K., Csizmadia, E., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202500419r · Cited by 1
Boucher, J. D., Stranford, D. M., Edelstein, H. I., Tullman‐Ercek, D., Kamat, N. P., & Leonard, J. N. (2026) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70258 · Cited by 1
“Upon intravitreal injection, EV-AAV2 outperformed free AAV2 in retinal transduction via delivery of GFP, increasing transduction of cell types that are transduced by free AAV2 as well as increasing the extent of transduction across different regions of the retina (Wassmer et al. 2017 ).”
Liang, J., Hei, X., Chen, L., Zou, Z., Ji, Y., Feng, L., Li, W., Zhuang, Y., Bai, B., Liang, R., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04763-x · Cited by 1
“…suffer from two critical bottlenecks that severely limit their therapeutic efficacy: insufficient penetration across the dense retinal layers and lack of specific targeting to photoreceptors, resulting in off-target distribution, rapid clearance, and low local concentration in the ONL [11, 12].”
Oh, S. W., Han, J., & Park, S. (2024) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2024.16 · Cited by 2
Recent advances on modeling retinal disease: Towards efficient gene/drug therapy
Dolatabadi, E. N., Zaky, M. R. A., Abbas, F. H., Milani, A. E., André, H., & Alizadeh, E. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110416 · Cited by 1
Henriques, C., Lopes, M. M., de Albuquerque, P. M. C., Rufino‐Ramos, D., Gaspar, L. S., Lobo, D. D., Leandro, K., da Silva, A. C., Baganha, R., Duarte, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.30.542901 · Cited by 1
“Moreover, it was observed that EV-AAVs transduce cells more efficiently than solo AAVs both in vitro and in vivo 14,15,39,16–19, 28, 36– 38 .”
Self-citationde Almeida, L. P., Henriques, C., Lopes, M. M., Albuquerque, P., Rufino‐Ramos, D., Gaspar, L. S., Lobo, D. D., Leandro, K., da Silva, A. B. G., Baganha, R., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3220758/v1 · Cited by 1
Self-citationNanovesicles for ocular drug delivery
Antimisiaris, S. G., & Natsaridis, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91865-7.00025-0
Vitrectomy and ILM peeling in rhesus macaque: pitfalls and tips for success
Pan, Q., Lu, S., Li, M., Pan, H., Wang, L., Mao, Y., Wu, W., & Zhang, Y. (2022) · Eye · doi:10.1038/s41433-022-02327-5
Cotto, H. A. M. (2024) · Digital Repository Service (Northeastern University) · doi:10.17760/d20659806
Potential of Extracellular Vesicles as Therapeutics in Retinal Diseases
Bosch, S., Lajunen, T., Merivaara, A., Rilla, K. J., & Urtti, A. (2024) · Biology of extracellular matrix · doi:10.1007/978-3-031-68811-9_8
Molecular and Digital Innovation in Pediatric Surgery
Sharrer, G. T. (2024) · Molecular Frontiers Journal · doi:10.1142/s2529732524500032 · Cited by 1
Exosomes for Ophthalmic Therapeutics
Tao, H., & Li, Z. (2012) · Springer eBooks · doi:10.1007/978-981-97-5536-3_10
The Applications of Exosomes in the Treatment of Autoimmune-Mediated Eye Diseases
Li, H., & Zhang, X. (2024) · Springer eBooks · doi:10.1007/978-981-97-5536-3_12
Exosomes and Exosome-Derived miRNAs: Current Knowledge and Future Aspects
Mao, K. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009102
Imaging of adeno-associated viral capsids for purposes of gene editing using CEST NMR/MRI
Lam, B. (2024) · eScholarship (California Digital Library)
Current Perspectives on the Biological Effects of Exosomes in Ophthalmic Diseases
Weng1, G. L. Q. (2026) · International Journal of Frontiers in Medicine · doi:10.25236/ijfm.2026.080105
“Similarly, exo-AAV2 showed enhanced traversal across the vitreous-retina barrier and augmented the transduction efficiency of retinal cleavage protein 1 (RS1) within the mouse retina, when compared to conventional AAV2[43].”
Targeted Delivery of Engineered Exosomes and the Advances for Their Applications in Ocular Tissue
Ju, Z., Shi, Y., Gao, L., Duan, W., & Liu, Y. (2026) · Current Eye Research · doi:10.1080/02713683.2026.2659098
“81 Exosomes derived from BMSC were demonstrated to enhance the neuroprotection of RGCs following intravitreal injection in glaucomatous animals.”
Single Particle Adsorption and Response Quantification for Functional AAVx Titer and Dose AnalysisPreprint
Nagaraj, C. K., Nugyen, T. K., Kwak, K. J., Bayazit, B., Huang, X., Newell, J. S., Doon‐Ralls, J., Rima, X. Y., Harper, S. Q., Saad, N. Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.28.728583
“…strategies that increase local AAVx density, such as encapsulation of multiple AAVx within extracellular vesicles, where a single EV carrying ~20-40 AAVx could function analogously to a SPARQ pattern that reliably produces a transduction event at substantially reduced systemic dose 3,45,46 .”
Exosome engineering: The promise and peril of targeted delivery for treating ocular diseases
Sharif, E., Hashemi, N., Eskandari, F., Shams, F., & Rekabgardan, M. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103664
Exosomes from mesenchymal stem/stromal cells and their therapeutic role in osteoarthritic pain
Kouroupis, D., Jergová, S., Sagen, J., & Best, T. M. (2026) · Journal of Experimental Orthopaedics · doi:10.1002/jeo2.70825
“…the use of EXO ‐ enveloped AAVs (EXOs ‐ AAVs) can improve transduction, prolong transgene expression, and increase resistance to human neutralising antibodies compared with standard AAVs when administered locally to diverse sites such as intravitreal, intracochlear and intracerebral [29, 60, 80].”
Lee, M., Choi, Y., Yoon, S., & Kim, M. (2026) · Molecules · doi:10.3390/molecules31203725
“…intravitreal injection might not be the best approach to treat AMD (age-related macular degeneration) with LNPs or EVs since AMD arises in RPE (retinal pigment epithelium) or choriocapillaris, and LNPs or EVs need to travel through multiple retinal layers and microglia to reach RPE cells [33–35].”
Metadata
- Authors
- Wassmer, S. J., Carvalho, L. S., György, B., Vandenberghe, L. H., & Maguire, C. A.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- Howard Hughes Medical Institute (US)
- Harvard University (US)
- Corresponding author
- György, Bence
- Vandenberghe, Luk H.
- Maguire, Casey A.
- Venue
- Scientific Reports
- Published
- 2017-03-31
- Volume
- 7
- Issue
- 1
- Pages
- 45329-45329
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5374486
- OpenAlex
- W2601308787
- Cited by
- 164
- References
- 46
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 17 · 2023: 22 · 2022: 13 · 2021: 23 · 2020: 26 · 2019: 11 · 2018: 8 · 2017: 8
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
- Funders
- Cure Alzheimer's Fund
- Grousbeck Family Foundation
- National Institutes of Health
- National Eye Institute (DP1EY023177)
- National Institute of Neurological Disorders and Stroke (P30NS045776)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus type 2, retinal gene delivery, intravitreal injection, exosomes, GFP expression, retinal cell types, Müller cells, photoreceptors
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Male, Retina, Gene Transfer Techniques, Green Fluorescent Proteins, Mice, Exosomes, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.